Nivolumab for Treatment of Squamous Cell Carcinoma of the Skin
Status:
Active, not recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
To determine the Objective Response Rate (ORR) of immunotherapy with Nivolumab in patients
with locally advanced/metastativ squamous cell carcinoma of the skin using Response Criteria
in Solid Tumors Version 1.1 (RECIST 1.1) per site assessment up to 2 years